Novartis Pharmaceuticals UK Limited
Novartis Pharmaceuticals UK Limited, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Great Britain. Established in 1996, the company has made significant strides in developing innovative healthcare solutions, focusing on areas such as oncology, cardiology, and immunology.
With a commitment to research and development, Novartis offers a diverse portfolio of unique products and services that address unmet medical needs. Their dedication to advancing patient care has positioned them as a leader in the UK market, recognised for their contributions to groundbreaking therapies.
Notable achievements include a strong emphasis on sustainability and access to medicines, reflecting their mission to improve and extend people's lives. As a trusted name in pharmaceuticals, Novartis continues to shape the future of healthcare in the UK and beyond.
+31 vs industry average
Novartis Pharmaceuticals UK Limited’s score of 69 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Novartis Pharmaceuticals UK Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Novartis Pharmaceuticals UK Limited's reported carbon emissions
Novartis Pharmaceuticals UK Limited, headquartered in GB and operating within the Pharmaceutical Preparation Manufacturing industry, reported a total of approximately 8.15 billion kg CO2e in 2022. This encompassed Scope 1 emissions totalling about 343.1 million kg CO2e, Scope 2 emissions of approximately 147.5 million kg CO2e, and Scope 3 emissions amounting to about 7.66 billion kg CO2e. In 2019, the company reported Scope 1 emissions from mobile combustion totalling about 124 million kg CO2e. While specific reduction targets for Novartis Pharmaceuticals UK Limited are not detailed in the provided data, the company's climate commitments are cascaded from its ultimate parent, Novartis AG. Novartis AG is a signatory to the Climate Pledge and is also involved with initiatives such as the Science Based Targets initiative (SBTi), RE100, and the Transition Pathway Initiative (TPI), indicating a broader corporate commitment to climate action. The data for Novartis Pharmaceuticals UK Limited is a current subsidiary, with performance data originating from the UK entity, while SBTi and other initiative targets are cascaded from Novartis AG.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Novartis Pharmaceuticals UK Limited’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Novartis Pharmaceuticals UK Limited yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Novartis AG
Carbon Disclosure Project
Inherited from Novartis AG
The Climate Pledge
Inherited from Novartis AG
UN Global Compact Climate Champions initiative
RE 100
Inherited from Novartis AG
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Novartis Pharmaceuticals UK Limited
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project